News Affimed and Roche ink $5bn plus cancer immunotherapy deal Deal is based on natural killer cell therapeutics
News AbbVie takes option on Argenx's cancer immunotherapy ARGX-115 is still in preclinical development
Views & Analysis Oncolytics: the dawn of a new era in cancer treatment Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunothera
News Novel cancer immunotherapy research lands Innovate UK fundin... New programme will leverage well-validated genetic mechanisms to promote cancer immunity.
News BI strikes billion-dollar cancer immunotherapy deal with OSE Could BI be looking to develop combination therapy?
News Roche's Tecentriq halts disease in squamous lung cancer Roche’s cancer immunotherapy Tecentriq has produced strong results which could give it the lead in a key lung cancer indication.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.